Pieris Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$4.80 | -$4.80 | -$4.80 |
| Q2 2024 | 1 | -$2.40 | -$2.40 | -$2.40 |
| Q3 2024 | 1 | -$4.00 | -$4.00 | -$4.00 |
| Q4 2024 | 1 | -$4.80 | -$4.80 | -$4.80 |
Pieris Pharmaceuticals, Inc. Earnings Date And Information
Pieris Pharmaceuticals, Inc. last posted its earnings results on Wednesday, May 15th, 2024. The company reported $-3.95 earnings per share for the quarter, missing analysts' consensus estimates of $-0.12 by $3.83. The company had revenue of 0 for the quarter and had revenue of 42.81 M for the year. Pieris Pharmaceuticals, Inc. has generated $-22 earnings per share over the last year ($-21.8 diluted earnings per share) and currently has a price-to-earnings ratio of -1.39. Pieris Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based on prior year's report dates.
Pieris Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$2.19 | $1.07 M | $0 | ||
| 08/14/2024 | Q2 2024 | -$2.76 | $2.24 M | $0 | ||
| 05/15/2024 | Q1 2024 | -$0.12 | -$3.95 | -3.83 | $53,000 | |
| 04/29/2024 | Q4 2023 | -$3.71 | $1.30 M | |||
| 11/14/2023 | Q3 2023 | -$8.80 | -$8.70 | 0.1 | $7.74 M | $19.52 M |
| 08/10/2023 | Q2 2023 | -$12.80 | $3.63 | 16.43 | $4.02 M | $20.06 M |
| 05/10/2023 | Q1 2023 | -$13.22 | $1.94 M | |||
| 03/31/2023 | Q4 2022 | -$8.68 | $5.85 M | |||
| 11/04/2022 | Q3 2022 | -$9.17 | $4.51 M | $5.37 M | ||
| 08/04/2022 | Q2 2022 | -$8.80 | -$0.14 | 8.66 | $10.47 M | $3.70 M |
| 05/11/2022 | Q1 2022 | -$9.60 | -$2.98 | 6.62 | $10.99 M | |
| 03/01/2022 | Q4 2021 | -$10.16 | $8.44 M | |||
| 11/02/2021 | Q3 2021 | -$19.20 | -$19.53 | -0.33 | $5.32 M | $4.06 M |
| 08/05/2021 | Q2 2021 | -$20.03 | $5.67 M | $3.29 M | ||
| 05/17/2021 | Q1 2021 | -$13.60 | -$5.93 | 7.67 | $15.63 M | |
| 03/31/2021 | Q4 2020 | -$20.57 | $1.88 M | |||
| 11/04/2020 | Q3 2020 | -$12.80 | -$21.03 | -8.23 | $11.72 M | $2.94 M |
| 08/10/2020 | Q2 2020 | -$14.40 | -$7.56 | 6.84 | $8.03 M | $11.25 M |
| 05/11/2020 | Q1 2020 | -$12.80 | -$5.21 | 7.59 | $13.26 M | |
| 03/13/2020 | Q4 2019 | -$20.00 | -$1.16 | 18.84 | $17.27 M |
Pieris Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Pieris Pharmaceuticals, Inc.'s earnings date?
Pieris Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based off last year's report dates.
-
How can I listen to Pieris Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Pieris Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Pieris Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Pieris Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Pieris Pharmaceuticals, Inc. generate each year?
Pieris Pharmaceuticals, Inc. (:PIRS) has a recorded annual revenue of $42.81 M.
-
How much profit does Pieris Pharmaceuticals, Inc. generate each year?
Pieris Pharmaceuticals, Inc. (:PIRS) has a recorded net income of $42.81 M. Pieris Pharmaceuticals, Inc. has generated $-21.8 earnings per share over the last four quarters.
-
What is Pieris Pharmaceuticals, Inc.'s price-to-earnings ratio?
Pieris Pharmaceuticals, Inc. (:PIRS) has a price-to-earnings ratio of -1.39 and price/earnings-to-growth ratio is -0.04.
